StockData
Novo Nordisk A S logo

Novo Nordisk A S (NVO) stock

NVONYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NONOF
Financials through fiscal 2025, year ended Dec 31, 2025Score 4/30
$40.70−0.90 (-2.16%)

Close on Nov 17, 2026Market cap $181.73BP/E 12.0Yield –

Novo Nordisk A S r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was 52.04B DKK, up 8.3% from the year before. Over ten years it grew 14.4% a year on average. The highest annual figure on record is 52.04B DKK in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 202552.04B DKK+8.3%
FY2024Dec 31, 202448.06B DKK+48.1%
FY2023Dec 31, 202332.44B DKK+34.9%
FY2022Dec 31, 202224.05B DKK+35.3%
FY2021Dec 31, 202117.77B DKK+14.9%
FY2020Dec 31, 202015.46B DKK+8.7%
FY2019Dec 31, 201914.22B DKK-4.0%
FY2018Dec 31, 201814.81B DKK+5.6%
FY2017Dec 31, 201714.01B DKK-3.8%
FY2016Dec 31, 201614.56B DKK+7.0%
FY2015Dec 31, 201513.61B DKK–

More Novo Nordisk A S figures

See a number that looks wrong?